

Analgesic drug to prevent post surgery neuropathic pain



HEALTH
NEUROLOGY

ERADICATE NEUROPATHIC PAIN WITH EXPECTED REDUCED SIDE-EFFECT

Neuropathic pain induced by surgical interventions is a major public health problem because available treatments display side-effects and weak efficiency.

Our research team has developed a new asset that consist in :

1 | Repurposing of **Memantine**, an antagonist of NMDA (N-Methyl-D-Aspartate) receptors usually prescribed for Alzheimer's disease to prevent neuropathic pain following surgical interventions like mastectomy.

2 | Reduction of analgesics consumption and improvement of emotional state




Competitive Advantages

- Response to unmet therapeutic need
- Attractive to speed up drug development
- Contribute to life quality improvement
- Preventive analgesic effects
- Non-opioid

Development Status

- **Clinical POC validated** in a randomized clinical trial on 40 women undergoing mastectomy.



Compared with placebo, patients receiving Memantine showed a significant reduction in post-mastectomy pain intensity, reduced use of analgesic at 3 months and an improved emotional state.

Business Opportunities

- Chronic pain treatment

#Keywords

Neuropathic pain
Drug repurposing
NMDA receptor antagonist
Memantine

Research Team

UMR 1107 Inserm/UCA
NEURO-DOL
Clermont-Ferrand, France
Pr. Gisèle PICKERING

Partnership

Licensing or co-development

Intellectual Property

FR2980973 / WO2013053746
Priority filing in 2011
Requests filed in EP / US

SATT | SOCIÉTÉ
D'ACCÉLÉRATION
DU TRANSFERT
DE TECHNOLOGIE
GRAND CENTRE

Contact

Magali **GRANGER**
Business Developer
T. +33 (0)6 34 22 36 89
magali.granger@sattgc.com

SATT Grand Centre

CLERMONT-FERRAND | LA ROCHELLE | LIMOGES |
ORLÉANS | POITIERS | TOURS

Head Office : 8, rue Pablo Picasso
63000 CLERMOND-FERRAND - FRANCE

www.sattgc.com